Role of thalidomide, senicapoc, and sodium butyrate in choroidal neovascularization.

Choroidal neovascularization (CNV) is the hallmark of wet age-related macular degeneration (AMD), a leading cause of irreversible blindness in the modern world. The objective for this study was to investigate the therapeutic potential of known antiangiogenic agents: thalidomide, senicapoc, and sodium butyrate. Dose-dependent effect of the agents on growth of ARPE-19 cells and human umbilical vein endothelial cells (HUVECs) was investigated with cell counting assays. Half-maximal inhibitory concentrations of thalidomide (765 μM and 1520 μM), senicapoc (50 μM and 79 μM), and sodium butyrate (933 μM and 557 μM) were determined for HUVECs and ARPE-19 cells, respectively. Immunofluorescence analysis showed decrease of VEGFA expression in both ARPE-19 cells and HUVECs after treatment only with thalidomide but not with senicapoc or sodium butyrate. Efficacy of the agents was studied in vivo with laser-induced CNV in C57BL/6 mice. Thalidomide (24 μg), senicapoc (4 μg), or sodium butyrate (100 μg) was intravitreally injected the day after CNV induction. Thalidomide, senicapoc, and sodium butyrate inhibited CNV size by 56%, 24%, and 21% respectively on day 7 post-laser. Thalidomide also reduced cobalt chloride induced increase of VEGFA mRNA in ARPE-19 (−33%) and protein in culture medium (−20%). Our results suggest that thalidomide may have more therapeutic potential than senicapoc or sodium butyrate for treatment of CNV or wet AMD. • Thalidomide is a potent inhibitor of CNV compared to senicapoc and sodium butyrate. • Sodium butyrate is toxic to retinal pigment epithelium. • Thalidomide is a very good anti-VEGF agent for HUVEC and ARPE-19 cells compared to senicapoc and sodium butyrate. • Thalidomide may have a potential therapeutic use in treating wet AMD. [ABSTRACT FROM AUTHOR]